Iconic Therapeutics
Manufacturing · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
701 Gateway Blvd Ste 100, South San Fran...Phone Number
(650) 437-1000Website
www.iconictherapeutics.comRevenue
$8.5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
1
1
1
1
About Iconic Therapeutics
Iconic Therapeutics, Inc. is a venture-backed biopharmaceutical company dedicated to translating an understanding of the role of Tissue Factor biology to new therapeutics for retinal disease, cancer, and potentially other serious diseases where Tissue Factor is over expressed. The company has developed a portfolio of proprietary molecules, which bind to and antagonize Tissue Factor expressed in disease, including in retina and in solid tumors.Explore more
Iconic Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Iconic Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Iconic Therapeutics recently announced quarterly report
Check out if Iconic Therapeutics is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Check if Iconic Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Iconic Therapeutics launches new products
Congratulate Masked Content for being promoted to Masked Content at Iconic Therapeutics
Iconic Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Iconic Therapeutics has new funding data
Click to see if Iconic Therapeutics had a recent Job posting/layoffs
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to Iconic Therapeutics
Compare insights from companies similar to Iconic Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Iconic Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Iconic Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Iconic Therapeutics.
Iconic Therapeutics financials insights
Gather financial insights about Iconic Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2004
Series A
$4.6M
2007
Other Financing Round
$1.3M
2009
Other Financing Round
$2.5M
2014
Series B
$20M
2016
Series C
$10M
Iconic Therapeutics Tech Stack
A closer look at the technologies used by Iconic Therapeutics
Most Recent Scoops
Lateral Move
Executive Move
Funding
, a biopharmaceutical company, recently secured $13.03 million in funding as part of a round targeted at $16.3 million.
Funding
Funding
Iconic Therapeutics recently secured $10 million in a Series C funding round.
Funding
Funding
Iconic Therapeutics recently secured $40 million in a Series C funding round.
Funding
Funding
Funding
Iconic Therapeutics News & Media
Exelixis and Iconic Therapeutics Amend Option and License Agreement for XB002, an Antibody-Drug Conjugate Targeting Tissue Factor
ALAMEDA, Calif. & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) and Iconic Therapeutics, Inc. (Iconic) today announced that the companies have amended the terms of their May 2019 exclusive option and license agreement for XB002 (formerly ICON-2), a next-generation tissue factor (TF)-targeting antibody-drug conjugate (ADC). Under the amended agreement announced today, Exelixis has acquired broad rights to use the anti-TF antibody incorporated into XB002, for any appDirk Sauer, Ph.D. Joins Iconic Therapeutics' Board of Directors
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Iconic Therapeutics, Inc., a clinical stage biopharmaceutical company dedicated to translating an understanding of Tissue Factor (TF) biology to new therapeutics for cancer, retinal disease and inflammation, today announced that Dirk Sauer, Ph.D., former Novartis Pharma AG’s Global Development Unit Head, Ophthalmology, has joined the company’s Board of Directors, bringing the current board membership to seven individuals. Dr. Sauer has been an ObserExelixis In-Licenses Iconic Therapeutics’ Tissue Factor-Targeting Antibody-Drug Conjugate Ahead of Planned Investigational New Drug Application
ALAMEDA, Calif., SOUTH SAN FRANCISCO, Calif. & VANCOUVER, British Columbia--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL), Iconic Therapeutics, Inc. (Iconic) and Zymeworks Inc. (NYSE:ZYME) today announced that Exelixis has exercised its exclusive option for Iconic’s lead oncology antibody-drug conjugate (ADC) program under the companies’ May 2019 agreement. As a result, Exelixis now has responsibility for the future clinical development, commercialization, and manufacturing of the Tissue FactoExelixis and Iconic Therapeutics Announce Promising Preclinical Data That Support Best-in-Class Potential for ICON-2 in Treatment of Solid Tumors
ALAMEDA, Calif. & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) and Iconic Therapeutics today announced new preclinical data that support the continued development of ICON-2, an ADC comprised of an anti-Tissue Factor (TF) antibody and Zymeworks’ proprietary linker-payload, for the treatment of diverse solid tumors. Exelixis has an exclusive option and license agreement for ICON-2 in oncology indications under its May 2019 agreement with Iconic Therapeutics, which d
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Iconic Therapeutics
Sign Up For FreeTo access detailed company insights
Iconic Therapeutics, Inc. is a venture-backed biopharmaceutical company dedicated to translating an understanding of the role of Tissue Factor biology to new therapeutics for retinal disease, cancer, and potentially other serious diseases where Tissue Factor is over expressed. The company has developed a portfolio of proprietary molecules, which bi... Read More
